Late cardiotoxicity of anthracyclines

Prescrire International

Volumn 8, Issue 43, 1999, Pages 145-146

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; NEOPLASM; TIME; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ARRHYTHMIA; CLINICAL TRIALS; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033207012     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Macrez C et al. "Accidents cardiaques observés au cours des traitements par la rubidomycine" Path Biol 1967; 15 (19-20): 949-953.
2. Weiss RB "The anthracyclines: will we ever find a better doxorubicin?" Semin Oncol 1992; 19 (6): 670-686.
3. "Doxorubicin hydrochloride". In: "Martindale The Extra Pharmacopoeia" 31st ed. The Pharmaceutical Press, London 1996: 567-569.
4. Shan K et al. "Anthracycline-induced cardiotoxicity" Ann Intern Med 1996; 125 (1): 47-58.
5. Steinherz LJ "Anthracyclin-induced cardiotoxicity" Ann Intern Med 1997; 126 (10): 827.
6. Abraham R et al. "A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy" Drug Safety 1996; 15 (6): 406-429.
7. Hale JP and Lewis LJ "Anthracyclines: cardiotoxicity and its prevention" Arch Dis Child 1994; 71: 457-462.
8. Pein F et al. "Aspects pédiatriques de la toxicité cardiaque des anthracyclines et implications pratiques pour sa prévention" Arch Pediatr 1995; 2: 988-999.
9. Von Hoff DD et al. "Risk factors for doxorubicin-induced congestive heart failure" Ann Intern Med 1979; 91 (5): 710-717.
10. Praga C et al. "Adriamycin cardiotoxicity: a survey of 1 273 patients" Cancer Treat Rep 1979; 63 (5): 827-834.
11. Von Hoff DD et al. "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases" Am J Med 1977; 62: 200-208.
12. "Dictionnaire Vidal" OVP Editions du Vidai Paris 1999.
13. Von Hoff DD et al. "The cardiotoxicity of anticancer agents" Semin Oncol 1982; 9 (1): 23-33.
14. Lipshultz SE et al. "Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer" N Engl J Med 1995; 332 (26): 1738-1743.
15. Lipshultz SE et al. "Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood" N Engl J Med 1991; 324 (12): 808-815.
16. Steinherz LJ et al. "Cardiac toxicity 4 to 20 years after completing anthracycline therapy" JAMA 1991; 266 (12): 1672-1677.
17. Steinherz LJ et al. "Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients" Med Pediatr Oncol 1995; 24: 352-361.
18. Sorensen K et al. "Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity" J Clin Oncol 1997; 15 (1): 61-68.
19. Musci M et al. "Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents" Transpl Proceedings 1997; 29: 578-579.
20. Haddy TB et al. "Late effects in long-term survivórs of high-grade non-Hodgkin's lymphomas" J Clin Oncol 1998; 16 (6): 2070-2079.
21. Ganz Wl et al. "Review of tests for monitoring doxorubicin-induced cardiomyopathy" Oncology 1996; 53: 461-470.
22. Steinherz LJ et al. "Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group" Pediatrics 1992; 89 (5): 942-949.
23. Lipshultz SE et al. "Monitoring for anthracycline cardiotoxicity" Pediatrics 1994; 93 (3): 433-437.
24. Bielack SS et al. "Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?" Eur J Cancer 1996; 32A (10): 1652-1660.
25. "Un point sur l'épirubicine" Rev Prescr 1992; 12 (118): 241-243.
26. "Idarubicin" Prescr Intern 1993; 2 (7): 101-103.
27. ○" Rev Prescr 1991; 11 (110): 404-405.
28. "Un point sur la mitoxantrone" Rev Prescr 1992; 12 (118): 240-241.
29. "Dexrazoxane" Prescr Intern 1997; 6 (32): 172-173.
30. Wiseman LR and Spencer CM "Dexrazoxane" Drugs 1998; 56 (3): 385-403.
31. Phillips KA and Tannock IF "Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy" J Clin Oncol 1998; 16 (9): 3179-3190.
32. "Liposomal daunorubicin" Prescr Intern 1998; 7 (34): 41-42.
33. "Liposomal doxorubicin" Prescr Intern 1998; 7 (35): 69-70.
34. ○ - arrêt de commercialisation" Rev Prescr 1994; 14 (145): 631.
35. Bessa E "Lettre des laboratoires Rhone-Poulenc Rorer à la revue Prescrire" 3 March 1998: 1 page.
36. Ryberg M et al. "Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer" J Clin Oncol 1998; 16 (11): 3502-3508.